AI Drug Discovery for GLP-1

AI drug discovery platforms including Recursion Pharmaceuticals and Insilico Medicine used large chemical language models to identify novel GLP-1 receptor agonists that could be manufactured at a fraction of the cost of Ozempic and Wegovy. The first AI-discovered obesity treatment entered Phase II clinical trials in 2025, compressing a process that traditionally takes 12+ years to under 3.